Sign in
Knowstox

Fundamentals snapshot

Gossamer Bio, Inc.

GOSS · NMS · Healthcare · Biotechnology

Current price

$8.77

52-week range

$8.51 - $309.60

Market cap

$53.64M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-14.86x Concerning

Net cash $16.96M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Gossamer Bio, Inc.

Gossamer Bio is a company working to create new medicines, like one called seralutinib, to help people with serious lung conditions. Their main focus is on getting this drug approved and sold in the United States, which is where most of their potential money will come from. This matters because if their drug is successful, it could help many patients and generate significant revenue for the company.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-32.03M FY2024 Q4 $-35.48M FY2025 Q1 $-39.75M FY2025 Q2 $-47.11M FY2025 Q3 $-36.17M FY2025 Q4 $-48.31M FY2026 Q1 $-38.72M FY2026 Q2 $-39.42M
Revenue $9.24M
Net income $16.90M
Diluted EPS -0.08
Operating cash flow $-39.42M
Free cash flow $-39.42M
Revenue $16.95M
Net income $-46.66M
Diluted EPS -0.20
Operating cash flow $-38.72M
Free cash flow $-38.72M
Revenue $13.80M
Net income $-47.24M
Diluted EPS -0.21
Operating cash flow $-48.31M
Free cash flow $-48.31M
Revenue $13.29M
Net income $-48.22M
Diluted EPS -0.21
Operating cash flow $-36.17M
Free cash flow $-36.17M
Revenue $11.49M
Net income $-38.27M
Diluted EPS -0.17
Operating cash flow $-47.06M
Free cash flow $-47.11M
Revenue $9.89M
Net income $-36.64M
Diluted EPS -0.16
Operating cash flow $-39.72M
Free cash flow $-39.75M
Revenue $9.38M
Net income $-33.03M
Diluted EPS -0.14
Operating cash flow $-35.48M
Free cash flow $-35.48M
Revenue $9.48M
Net income $-30.80M
Diluted EPS -0.14
Operating cash flow $-32.03M
Free cash flow $-32.03M

Is it cheap or expensive?

Fair value — vs current price $8.77

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $17.0M - more cash than debt. Interest coverage -14.9x.

Net debt $-16.96M
Interest coverage -14.86x
Healthy
Worse cushion Baseline Better cushion
GOSS BASELINE Gossamer Bio, Inc.

Total debt $40.07M Interest coverage -14.86x This is the baseline the peer rows are being compared against.

-14.86x

What you should know

The case for and against GOSS

1 Reward 0 Risks

Rewards

  • Revenue grew 9.9% last year.

Risks

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-0.56x
P/B
-0.57x
P/S
1.01x
EV/EBITDA
-0.23x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
100.0%
Operating margin
-282.2%
Net margin
-235.0%
ROE
—
ROA
-62.4%

Health

Liquidity and balance-sheet strength

Debt / equity
—
Current ratio
0.53x
Quick ratio
0.46x
Total debt
$40.07M
Total cash
$57.03M

Growth

How the business has been compounding

Revenue TTM
$53.29M
Revenue 5Y CAGR
—
EPS TTM
-48.10
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-162.63M
Free CF TTM
$-171.34M
FCF margin
-321.6%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—